Pharma industry committed to supplying quality drugs in India, world: IPA

IPA Secretary General Jain said, the Indian pharmaceutical industry has outshone itself as a consistent and reliable supplier of life-saving medicines to India and the world

pharma, medicines, drugs
"It has played a leading role in reducing the cost of medicines especially for the developing countries," PM added.
Press Trust of India New Delhi
2 min read Last Updated : Jul 09 2020 | 8:16 PM IST
Indian pharma industry is committed to an uninterrupted supply of quality medicines to patients in India and globally, Indian Pharmaceutical Alliance (IPA) said on Thursday.

The Prime Minister's speech at the India Global Week 2020 captures the strength of India's pharma industry. During these unprecedented times, the pharmaceutical industry worked in an integrated manner with the Indian government to ensure fulfilling domestic demand and meet export obligations and truly lived up to its title as the 'Pharmacy of the World'," IPA Secretary General Sudarshan Jain said in a statement.

Prime Minister Narendra Modi in his inaugural address at the India Global Week 2020 saidthe pandemic has once again shown that India's pharma industry is an asset not just for India but for the entire world.
"It has played a leading role in reducing the cost of medicines especially for the developing countries," he added.

Jain said time and again, the Indian pharmaceutical industry has outshone itself as a consistent and reliable supplier of life-saving medicines to India and the world.

"At a time when the world was grappling to ease out supply chain disruptions as a result of the lockdown, Indian pharma industry collectively rose to the challenge and assured uninterrupted supply of medicines to several countries to aid their fight against Covid-19," he added.

As the industry makes a shift towards self-reliance, international collaborations will add much needed impetus to the vision of providing access to quality medicines, Jain said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusPharma industryMedicines

Next Story